Table 2.

Underlying malignancies in children with COVID-19

Malignancy	n (%)
Hematolymphoid
Leukemias
B cell-Acute lymphoblastic leukemia	42 (34.4)
Standard risk	6
Intermediate risk	9
High risk	27
T cell-Acute lymphoblastic leukemia	15 (12.3)
Relapsed acute lymphoblastic leukemia	8 (6.6)
Acute myeloid leukemia	6 (4.9)
Mixed phenotypic acute leukemia (relapse-1)	2 (1.6)
Chronic myeloid leukemia in blast crisis	1 (0.8)
Relapsed acute promyelocytic leukemia	1 (0.8)
Lymphomas
T-lymphoblastic lymphoma	2 (1.6)
Burkitt lymphoma	3 (2.5)
Anaplastic large cell lymphoma (relapse-1)	5 (4.1)
Solid
Osteosarcoma (relapse-1)	8 (6.6)
Ewing sarcoma	6 (4.9)
Giant cell tumor	1 (0.8)
Undifferentiated sarcoma	2 (1.6)
Rhabdomyosarcoma	2 (1.6)
Neuroblastoma	2 (1.6)
Hepatoblastoma	3 (2.5)
Wilm tumor	3 (2.5)
CCSK	1 (0.8)
Embryonal sarcoma of liver	1 (0.8)
Relapsed retinoblastoma (CNS relapse)	1 (0.8)
Germ cell tumor	1 (0.8)
Low-grade glioma	3 (2.5)
Ependymoma	1 (0.8)
Pineoblastoma	1 (0.8)
Medulloblastoma	1 (0.8)
Nasopharyngeal carcinoma	1 (0.8)